(Total Views: 823)
Posted On: 10/01/2020 3:02:46 AM
Post# of 154284
Why so many deaths? We know early on from NP that there were many deaths in the trial. When the trial was leronlimab vs. only placebo doctors wouldn't want to push the trial to patients and patients would have been loathe to use it unless it was a last chance measure. Better to get something that might have the possibility of working then chance getting nothing,
So around half the patients on the placebo/SOC arm would be on placebo and would be the equivalent of our EIND patients that were at the worst stage. Being on placebo in those circumstances might account for half or more of those 45 deaths.
Now take into account what drugs were most likely given under SOC - remdesiver HCQ, IL-6 inhibitors and maybe in the rare case corticosteroids. Doctors would have still veered toward the worst cases given how badly the first three perform. So it's no surprise to consider that maybe half or more in the placebo/SOC arm died.
Outside of the Montefiore patients with multiple organ failure we know how well leronlimab performs.
So around half the patients on the placebo/SOC arm would be on placebo and would be the equivalent of our EIND patients that were at the worst stage. Being on placebo in those circumstances might account for half or more of those 45 deaths.
Now take into account what drugs were most likely given under SOC - remdesiver HCQ, IL-6 inhibitors and maybe in the rare case corticosteroids. Doctors would have still veered toward the worst cases given how badly the first three perform. So it's no surprise to consider that maybe half or more in the placebo/SOC arm died.
Outside of the Montefiore patients with multiple organ failure we know how well leronlimab performs.
(10)
(0)
